Eli Lilly
CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major catalyst for the rollout of the company’s closely watched experimental weight loss pill, orforglipron.
In an exclusive interview with CNBC, Ricks said Lilly expects to have Medicare coverage for the treatment “immediately following that launch, and that will change the game a bit too.”
He said that’s because many patients are currently paying in cash for competitor Novo Nordisk
’s GLP-1 pill for obesity. That launched earlier this month and is off to a strong start, even with spotty insurance coverage.
